{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T20:14:57Z","timestamp":1784060097535,"version":"3.55.0"},"reference-count":38,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,2,15]]},"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Evaluate the impact of sex on tofacitinib efficacy, safety and persistence (time to discontinuation) in patients with psoriatic arthritis (PsA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data were pooled from two phase 3 randomised controlled trials. Patients were randomised to tofacitinib 5\u2009mg or 10\u2009mg two times per day, adalimumab 40\u2009mg every 2 weeks or placebo. Efficacy outcomes to month 12 included American College of Rheumatology (ACR)20\/50\/70, minimal disease activity (MDA), Psoriasis Area Severity Index (PASI)75, change from baseline (\u2206) in Health Assessment Questionnaire-Disability Index (HAQ-DI) and \u2206Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F). Safety was assessed to month 12 and persistence was assessed to month 42 of a long-term extension study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 816 patients were included (54.3% females). At baseline, higher tender joint counts, enthesitis scores and worse HAQ-DI and FACIT-F were reported in females versus males; presence of dactylitis and PASI were greater in males versus females. At month 3, tofacitinib efficacy generally exceeded placebo in both sexes. Overall, similar ACR20\/50\/70, PASI75, \u2206HAQ-DI and \u2206FACIT-F were observed for tofacitinib between sexes; females were less likely to achieve MDA. Similar proportions of males\/females receiving tofacitinib (both doses) experienced treatment-emergent adverse events (AEs). Serious AEs occurred in 3.4%\/6.6% and 4.0%\/5.9% males\/females with tofacitinib 5\u2009mg and 10\u2009mg two times per day. Persistence was generally similar between sexes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Tofacitinib efficacy exceeded placebo in both sexes and was comparable between sexes. Consistent with previous studies of PsA treatments, females were less likely to achieve MDA, likely due to baseline differences. Safety and time to discontinuation were generally similar between sexes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01877668\">NCT01877668<\/jats:ext-link>; <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01882439\">NCT01882439<\/jats:ext-link>; <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01976364\">NCT01976364<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002718","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T11:31:34Z","timestamp":1679571094000},"page":"e002718","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct01877668","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01882439","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01976364","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01877668","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01882439","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01976364","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1473-1715","authenticated-orcid":false,"given":"Lihi","family":"Eder","sequence":"first","affiliation":[{"name":"Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna D","family":"Gladman","sequence":"additional","affiliation":[{"name":"Schroeder Arthritis Institute and Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip","family":"Mease","sequence":"additional","affiliation":[{"name":"Swedish Medical Center\/Providence St Joseph Health and the University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remy A","family":"Pollock","sequence":"additional","affiliation":[{"name":"Pfizer Canada ULC, Kirkland, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayana","family":"Luna","sequence":"additional","affiliation":[{"name":"Pfizer Canada ULC, Kirkland, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8792-4449","authenticated-orcid":false,"given":"Sibel Z","family":"Aydin","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[{"name":"Departments of Medicine\/Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Polachek","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gruben","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jane","family":"Cadatal","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Manila, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Kinch","sequence":"additional","affiliation":[{"name":"Pfizer Canada ULC, Kirkland, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4978-4072","authenticated-orcid":false,"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[{"name":"Division of Immunology\/Rheumatology, Stanford University, Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"2025090312295114000_9.1.e002718.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2025090312295114000_9.1.e002718.2","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.9592.1","article-title":"Recent advances in understanding and managing psoriatic arthritis","volume":"5","author":"Gladman","year":"2016","journal-title":"F1000Res"},{"key":"2025090312295114000_9.1.e002718.3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key140"},{"key":"2025090312295114000_9.1.e002718.4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181272"},{"key":"2025090312295114000_9.1.e002718.5","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1007\/s10067-017-3769-4","article-title":"A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors","volume":"36","author":"Chimenti","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2025090312295114000_9.1.e002718.6","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/rheumatology\/kex387","article-title":"Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis","volume":"57","author":"Stober","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312295114000_9.1.e002718.7","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1007\/s10067-020-05027-1","article-title":"Retention rates and identification of factors associated with anti-TNF\u03b1, anti-IL17, and anti-IL12\/23R agents discontinuation in psoriatic arthritis patients: results from a real-world clinical setting","volume":"39","author":"Navarini","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2025090312295114000_9.1.e002718.8","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001519","article-title":"Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study","volume":"7","author":"Ramonda","year":"2021","journal-title":"RMD Open"},{"key":"2025090312295114000_9.1.e002718.9","doi-asserted-by":"crossref","DOI":"10.1093\/rap\/rkaa070","article-title":"Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden","volume":"4","author":"Geale","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"2025090312295114000_9.1.e002718.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201357"},{"key":"2025090312295114000_9.1.e002718.11","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/acr.24090","article-title":"Determinants of patient-reported psoriatic arthritis impact of disease: an analysis of the association with sex in 458 patients from fourteen countries","volume":"72","author":"Orbai","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312295114000_9.1.e002718.12","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/482691","article-title":"Clinical differences between men and women with psoriatic arthritis: relevance of the analysis of genes and polymorphisms in the major histocompatibility complex region and of the age at onset of psoriasis","volume":"2013","author":"Queiro","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"2025090312295114000_9.1.e002718.13","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3711","article-title":"Effect of sex in systemic psoriasis therapy: differences in prescription, effectiveness and safety in the BIOBADADERM prospective cohort","volume":"101","author":"Hern\u00e1ndez-Fern\u00e1ndez","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"2025090312295114000_9.1.e002718.14","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/ced.14218","article-title":"Sex- and gender-associated clinical and psychosocial characteristics of patients with psoriasis","volume":"45","author":"Napolitano","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"2025090312295114000_9.1.e002718.15","doi-asserted-by":"crossref","DOI":"10.1186\/ar2670","article-title":"Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register","volume":"11","author":"Saad","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"2025090312295114000_9.1.e002718.16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.111856"},{"key":"2025090312295114000_9.1.e002718.17","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40744-022-00445-w","article-title":"Responses to ixekizumab in male and female patients with psoriatic arthritis: results from two randomized, phase 3 clinical trials","volume":"9","author":"Eder","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2025090312295114000_9.1.e002718.18","article-title":"Comparison of secukinumab versus adalimumab efficacy by sex in psoriatic arthritis from a phase 3b, double-blinded, randomized, active-controlled study","volume":"72","author":"Wright","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025090312295114000_9.1.e002718.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"2025090312295114000_9.1.e002718.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615977"},{"key":"2025090312295114000_9.1.e002718.21","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S2665-9913(21)00010-2","article-title":"Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study","volume":"3","author":"Nash","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2025090312295114000_9.1.e002718.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"2025090312295114000_9.1.e002718.23","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S2665-9913(20)30339-8","article-title":"Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance","volume":"3","author":"Nash","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2025090312295114000_9.1.e002718.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.359"},{"key":"2025090312295114000_9.1.e002718.25","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220948"},{"key":"2025090312295114000_9.1.e002718.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2008.12.001"},{"key":"2025090312295114000_9.1.e002718.27","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/BOR.0000000000000388","article-title":"Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment","volume":"29","author":"Mease","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"2025090312295114000_9.1.e002718.28","doi-asserted-by":"crossref","DOI":"10.1186\/ar2591","article-title":"Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study","volume":"11","author":"Sokka","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"2025090312295114000_9.1.e002718.29","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.211037"},{"key":"2025090312295114000_9.1.e002718.30","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150805"},{"key":"2025090312295114000_9.1.e002718.31","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/acr.22529","article-title":"Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis","volume":"67","author":"Haddad","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312295114000_9.1.e002718.32","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1277-1","article-title":"Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study","volume":"19","author":"Queiro","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025090312295114000_9.1.e002718.33","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002195","article-title":"Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies","volume":"8","author":"Ritchlin","year":"2022","journal-title":"RMD Open"},{"key":"2025090312295114000_9.1.e002718.34","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151491"},{"key":"2025090312295114000_9.1.e002718.35","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/acr.24593","article-title":"Depression and anxiety reduce the probability of achieving a state of sustained minimal disease activity in patients with psoriatic arthritis","volume":"74","author":"Wong","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312295114000_9.1.e002718.36","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130797"},{"key":"2025090312295114000_9.1.e002718.37","doi-asserted-by":"publisher","DOI":"10.1002\/art.30117"},{"key":"2025090312295114000_9.1.e002718.38","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40744-021-00286-z","article-title":"Real-world treatment persistence with biologic disease-modifying antirheumatic drugs among german patients with psoriatic arthritis\u2014a retrospective database study","volume":"8","author":"Sewerin","year":"2021","journal-title":"Rheumatol Ther"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002718","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:30:01Z","timestamp":1756927801000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,3,23]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1136\/rmdopen-2022-002718"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002718","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}